Consensus AbbVie Inc.

Stocks

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX 14:56:29 2026-10-22 EDT			5-day change	1st Jan Change
284.81 ^USD	+0.00%		+0.36%	+24.47%

12:54pm	Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says	MT
12:51pm	AbbVie Announces Positive Topline Results From The Phase 3 INTREPID Study Evaluating Lutikizumab In Adults And Adolescents With Moderate To Severe Hidradenitis Suppurativa	CI

Evolution of the Average Target: AbbVie Inc.

Evolution of the Target Price: AbbVie Inc.

Changes in Analyst Recommendations: AbbVie Inc.

86685c0194feaf9682709beaa18dab.3aY-MGic1ESeC0kr3CCjVMY2pE9ejRguCqzRR9LAp6g.6uoMahjKjSDybh9DuVTTBKFO7j4U4k92Xvq-dbG1wNDt_kZhIdqDPtlCAA~68b615f978b163d25178051632649b66

Analysts' recommendations: AbbVie Inc.

12:54pm	Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says	MT
08:57am	Goldman Sachs Adjusts Price Target on AbbVie to $294 From $258	MT
10-21	BofA: UCB's Bimzelx Sets 'Very High' Bar Ahead of Q4 Competitor Data in Hidradenitis Suppurativa	MT
10-21	Barclays Adjusts Price Target on AbbVie to $325 From $300	MT
10-20	Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says	MT
10-20	Global markets live: Google, Apple, Amazon, 3M, Waymo…
10-13	AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says	MT
10-09	UBS Adjusts Price Target on AbbVie to $275 From $260, Maintains Neutral Rating	MT
10-09	BofA Securities Adjusts AbbVie Price Target to $305 From $289	MT
10-08	Cantor Fitzgerald Adjusts Price Target on AbbVie to $290 From $285	MT
10-08	JPMorgan Adjusts Price Target on AbbVie to $300 From $285	MT
10-07	Morgan Stanley Adjusts Price Target on AbbVie to $310 From $296	MT
10-06	AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says	MT
10-06	Scotiabank Adjusts Price Target on AbbVie to $320 From $280, Maintains Sector Outperform Rating	MT
09-29	AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says	MT
09-29	BofA Securities Adjusts AbbVie Price Target to $289 From $282, Maintains Buy Rating	MT
09-24	Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says	MT
09-10	HSBC Adjusts Price Target on AbbVie to $315 From $300, Keeps Buy Rating	MT
09-08	BofA Securities Adjusts Price Target on AbbVie to $282 From $276	MT
08-20	Piper Sandler Adjusts Price Target on AbbVie to $303 From $298, Maintains Overweight Rating	MT
08-17	Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating	MT
08-13	Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300	MT
08-11	BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating	MT
08-05	Argus Lifts AbbVie Price Target to $270 From $250	MT
08-05	Leerink Partners Adjusts Price Target on AbbVie to $279 From $245	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBVIE INC.					-0.46%
	ELI LILLY AND COMPANY					+4.78%
	JOHNSON & JOHNSON					+8.39%
	ROCHE HOLDING AG					-2.05%
	MERCK & CO., INC.					+5.79%
	NOVARTIS AG					-2.49%
	ASTRAZENECA PLC					+24.34%
	AMGEN INC.					-9.73%
	GILEAD SCIENCES, INC.					+4.29%
	NOVO NORDISK A/S					+13.9%
	Average					+4.68%
	Weighted average by Cap.					+4.41%